MAPT and Alzheimer disease: Several AD biomarkers, including cerebrospinal fluid (CSF) [8] and positron emission tomography (PET) imaging of amyloid and tau proteins [9, 10], have been extensively validated and show high sensitivities and specificities, but their levels do not provide the desired information with respect to staging the disease process.